GenFleet Therapeutics (Shanghai) Inc. will convene its 2026 Annual General Meeting on 11 May 2026 at 10:00 a.m. in the company’s meeting room at Building 73, Lane 1000, Zhangheng Road, Pudong New Area, Shanghai. Shareholders will vote on a series of ordinary and special resolutions that frame the company’s governance, financial reporting and capital-management agenda for the coming year.
Key business items include:
• 2025 Performance Review: Investors will be asked to endorse the Board Report, the audited consolidated financial statements and the full 2025 annual report.
• Remuneration Oversight: The AGM will review director compensation packages for both 2025 and 2026.
• Auditor Continuity: The Board proposes to re-appoint Ernst & Young as external auditor for 2026 and seeks authority to negotiate remuneration and finalize related agreements.
• Corporate Governance Updates: Amendments to the Working Rules for Independent Non-executive Directors and to the Related Party Transaction Management System are scheduled for shareholder approval.
• Capital Management Mandates: Two special resolutions would authorise the Board to (i) repurchase H shares under a general mandate and (ii) issue new shares or dispose of treasury shares. Additional resolutions aim to update the procedural rules for shareholder meetings and for the Board of Directors.
Shareholders of both H shares and unlisted shares can appoint proxies to vote; completed proxy forms must reach Computershare Hong Kong Investor Services Limited or the company’s Shanghai office no later than 24 hours before the meeting. Completion of a proxy form will not preclude holders from attending and voting in person.
The proxy circular, dated 17 April 2026, contains the full text of each resolution and detailed voting instructions, ensuring transparency ahead of the May meeting.
Comments